Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somewhat Late To The HCV Race, Novartis Licenses NS5A Inhibitor From Enanta

This article was originally published in The Pink Sheet Daily

Executive Summary

The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.

You may also be interested in...



Deal Watch: Tax Policy Changes Claiming Victims Already, As Salix/Cosmo Plans Abandoned

Abandoned deals were the order of the week as the Salix/Cosmo breakup followed Novartis’ exit from hepatitis C drug development and a partnership in that space with Enanta. J&J, however, increased its bet on HCV by acquiring Alios, one of several noteworthy buyouts occurring during the week.

IPOs: Enanta Wows While Tetraphase Gets The Job Done

A pair of biotech IPOs priced on March 20 with mixed results. Hepatitis C developer Enanta got a warm reception from investors looking to tap into what has been a lucrative sector. But antibiotics company Tetraphase priced below its range and traded flat.

Novartis And Idenix Break Up

Novartis and Idenix have all but ended the co-development and commercialization agreement that was established in 2003 and gave Novartis a controlling option in the company.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel